There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bio-Techne (TECH – Research Report), Gilead Sciences (GILD – Research Report) and Blueprint Medicines (BPMC – Research Report) with bullish sentiments.
Bio-Techne (TECH)
Scotiabank analyst Sung Ji Nam maintained a Buy rating on Bio-Techne today and set a price target of $83.00. The company’s shares closed last Thursday at $74.08.
According to TipRanks.com, Nam has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Bio-Techne is a Strong Buy with an average price target of $79.71, an 8.5% upside from current levels. In a report issued on April 18, Deutsche Bank also maintained a Buy rating on the stock with a $82.00 price target.
See today’s best-performing stocks on TipRanks >>
Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Buy rating on Gilead Sciences yesterday. The company’s shares closed last Thursday at $65.01, close to its 52-week low of $64.63.
According to TipRanks.com, Okunewitch ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $81.70 average price target, a 24.7% upside from current levels. In a report issued on April 19, Oppenheimer also maintained a Buy rating on the stock with a $105.00 price target.
Blueprint Medicines (BPMC)
In a report released today, Ami Fadia from Needham maintained a Buy rating on Blueprint Medicines, with a price target of $97.00. The company’s shares closed last Thursday at $101.59.
According to TipRanks.com, Fadia is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $98.33 average price target, representing a 3.7% upside. In a report issued on April 26, H.C. Wainwright also maintained a Buy rating on the stock with a $125.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TECH:
